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Abstract : Anti-androgen therapy has been proposed to be effective in the treat-
ment of androgen receptor （AR）-positive triple negative breast cancer （TNBC）.  
Herein, we report on the case of a 91-year-old female patient with AR-positive 
TNBC who underwent anti-androgen therapy and had a good response.  Because 
of dementia, the patient lives in an aged care facility.  It was here that a staff 
member noticed a mass with a rash on the patient’s breast.  Consequently, the 
patient was sent for further examination.  Ultrasonography revealed an irregularly 
shaped, indistinct hypoechoic mass measuring 19×18×9 mm located in the upper 
outer quadrant of the left breast.  Core needle biopsy （CNB） was performed and 
the mass was diagnosed as apocrine carcinoma.  Further immunohistochemical 
analysis showed that the mass was AR-positive TNBC.  Anti-androgen therapy was 
determined to be the optimal treatment option for this patient.  The Institutional 
Review Board approval the off-label use of an anti-androgen for the treatment of 
this patient, who was subsequently treated with the anti-androgen utamide.  After 
8 months, the size of the tumor had reduced to 15×9×5 mm.
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Introduction
　Triple negative breast cancer （TNBC） is a breast cancer subtype defined by a lack of 
expression of both estrogen （ER） and progesterone （PR） receptors, as well as a lack of 
overexpression of human epidermal growth factor receptor 2 （HER2）.  This subtype of breast 
cancer is associated with aggressive behavior and poor prognosis.  To date, only chemotherapy 
has been found to be effective for in the treatment of TNBC and no therapeutic targets have 
yet been established.
　Recently, gene expression profiling identified six distinct molecular subtypes of TNBC: two 
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basal types （BL1 and BL2）, two mesenchymal-like subgroups （M and MSL）, an immunomodu-
latory group （IM）, and a luminal androgen group （LAR）.  The prevalence of LAR tumors is 
11% （62/587） of TNBCs or 2 % （62/3247） of all breast cancers.  Importantly, the LAR subtype 
is characterized by androgen receptor （AR） signaling and it has been shown to be sensitive to 
bicalutamide, an AR antagonist, both in vitro and in xenograft models1）.  Therefore, therapies 
targeting the AR may be effective against tumors that express this hormone receptor.
　Herein we report on the case of a patient with AR-positive triple negative apocrine carcinoma 
who underwent anti-androgen therapy and had a good response.
Case report
　A 91-year-old female patient, who suffers from dementia and lives in an aged care facility, vis-
ited Showa University Hospital in March 2012 because a staff member at the aged care facility 
had noticed a mass with a rash on the patient’s left breast 3 weeks earlier.
　Physical examination revealed an elastic, hard, protuberant tumor with an irregular surface 
just beneath the skin.  Neither axillary nor supraclavicular lymph nodes were palpable.  Ultra-
sonography revealed an irregularly shaped, hypoechoic mass with an indistinct margin measuring 
19×18×9 mm located at the upper outer quadrant of the left breast （Fig. 1a）.  Mammography 
and magnetic resonance imaging were not performed because the patient could not keep still. 
Indeed, for the core needle biopsy （CNB）, the patient’s family and a nurse were required to 
help hold her down.  Diagnosis of the biopsy revealed that the tumor was apocrine carcinoma, 
as indicated by cancer cells with large, round nuclei and plump, eosinophilic, granular, and sharp-
bordered cytoplasm （Fig. 2a）.  The nuclear grade was determined to be 1.  Immunohistochemi-
cal staining of the biopsy specimen revealed that the cancer was negative for ER, PR, and 
HER2, and the Ki67 index was 10%-20%.  It was decided that surgery under general anes-
thesia and hospital care would worsen the patient’s general status and that surgery under local 
anesthesia would be impossible based on the difculties encountered when performing the CNB. 
Moreover, because the patient’s cancer was both ER- and PR-negative, hormone therapy was 
Fig. 1.  （a） Ultrasonography before the patient started flutamide revealed an irregularly shaped, hypoechoic mass 
with an indistinct margin measuring 19×18×9 mm located at the upper outer quadrant of the left breast.
（b） After 8 months treatment with flutamide, the size of the tumor had reduced to 15×9×5 mm.
（a） （b）
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not an option despite her general condition.  We thought that anti-androgen therapy may be an 
effective alternative treatment that would be less damaging than chemotherapy if the tumor was 
AR positive.  Indeed, we reasoned that anti-androgen therapy could control cancer progression 
without signicantly affecting the patient’s quality of life.  Consequently, we determined the AR 
status of the tumor using the clone AR27 antibody （Novocastra） and the results were positive 
（Fig. 2b）.  Approval was then obtained from the Institutional Review Board to commence off-
label anti-androgen therapy for the patient, which was also explained in detail to her family. 
The patient’s family provided written informed consent and the patient was prescribed a daily 
dose of 250 mg flutamide, an anti-androgen.  After 1 month, the size of the tumor size had 
reduced to 19×12×7 mm, and the tumor continued to shrink over a period of 8 months to 15×
9×5 mm （Fig. 1b）.  No obvious adverse events were observed, including changes to blood com-
ponents as determined by blood testing.  After 1 year, an abnormal vaginal discharge was noted, 
but further gynecological examinations could not be performed because of the patient’s dementia, 
and it was unclear whether this discharge was caused by the utamide treatment.  At the time 
of writing, 1 year and 10 months after starting on utamide therapy, the patient remains alive.
Discussion
　The LAR subgroup of TNBC has been reported to be driven by AR signaling.  In addition, 
these tumors have been shown to be sensitive to the effects of anti-androgens in vitro and in 
xenograft models1）.  Therefore, it has been proposed that anti-androgen therapy may be effective 
for the treatment of AR-positive TNBC, which is frequently seen in apocrine carcinoma2）.  Con-
sequently, clinical trials are underway using anti-androgen therapy3）.
　The AR is a nuclear receptor that binds testosterone and dihydrotestosterone in the cyto-
Fig. 2.  （a） Diagnosis of the biopsy revealed that it was apocrine carcinoma, as indicated by cancer cells with 
large, round nuclei and plump, eosinophilic, granular, and sharp-bordered cytoplasm （hematoxylin and 
eosin ［H&E］; original magnification×400）. 
　　　  （b） The tumor was androgen receptor positive, as determined by immunohistochemistry using the 
clone AR27 antibody （Novocastra; original magnification×100）.
（a） （b）
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plasm, then translocates to the nucleus, where it regulates gene transcription.  The AR has been 
reported to be expressed in 70%-80% of breast cancers and in 10%-43% of TNBCs2，4–11）.
　The role of AR expression in TNBC is unclear.  Many studies have documented that AR 
expression in TNBC is associated with favorable prognostic factors, including lack of lymph node 
metastasis7，8）, low histological grade2，7，9）, long disease-free and overall survival7，8）, and low rates 
of recurrence and distant metastasis9） （Table 1）.  Tsutsumi reported that the mean Ki-67 labeling 
index, an indicator of proliferation, was higher in AR-negative than AR-positive TNBC （58% vs 
37%, respectively; P ＜ 0.01）2）.  Together, these results suggest that AR-positive TNBC is associ-
ated with a less aggressive phenotype.
　In contrast with these observations, some reports suggest that AR positivity is associated with 
negative features in TNBC.  McGhan et al 10） observed that there was a tendency for more 
advanced disease in AR-positive than AR-negative TNBC patients, as indicated by a greater pro-
portion of patients with Stage II and III tumors （73% vs 44%）, angiolymphatic invasion （27% vs 
19%）, lymph node metastases （45% vs 14%）, and a larger mean tumor size （2.9 vs 2.2 cm） in 
the former group.  In that study, Stage I and II patients had similar recurrence-free and overall 
survival rates regardless of AR status10）.  In contrast, patients with Stage III AR-positive TNBC 
had a worse prognosis than AR-negative TNBC patients, although this trend was not statistically 
signicant.  This may imply a degree of chemotherapy resistance in the AR-positive subgroup10）. 
Hu et al 11） observed that overall mortality was 83% higher in women with AR-positive TNBC 
Table 1.  Comparison of major studies investigating the clinical features of androgen receptor-positive triple-negative 
breast cancer
Study Year
No. 
patients
No. AR+ Positivity
LN 
metastasis
Grade
DFS, 
OS
Other observations
Tsutsumi et al.2） 2012 51 21（41％） ≥ 1 % LowerA
Ki-67 labeling was higher in 
AR-negative TNBC
Luo et al.7） 2010 137 38 （28％） H score Negative LowerA LongerA
AR positivity was associated 
with postmenopausal status
He et al.8） 2012 287 74 （26％） ≥ 5 % Negative LongerA
Rakha et al.9） 2007 282 36 （13％） ＞ 0 % LowerA
In node-positive patients, AR 
negativity was associated with 
the development of recurrence 
and distant metastasis
McGhan et al.10） 2013 94 22 （23％） ≥ 10 % Positive
AR positivity was associated 
with an older patient age and a 
higher TNM stage
Hu et al.11） 2011 211 78 （37％） ≥ 1 % ShorterA
ACompared with androgen receptor-positive triple-negative breast cancer.
Positivity：The judging criteria of the immunostaining as androgen receptor-positive.
AR, androgen receptor; LN, lymph node; DFS, disease-free survival; OS, overall survival; TNBC, triple negative 
breast cancer; TNM, tumor-node-metastasis.
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than in women with AR-negative TNBC （multivariate hazard ratio 1.83; 95% condence interval 
［CI］ 1.11-3.01; P＝ 0.02）.
　There are many possible reasons for the apparent discrepancies between studies regarding 
the relationship between AR expression and the clinicopathological features of TNBC, including 
variations in the denition of AR positivity and the approaches used for its detection （e.g. type 
of antibody clone, antibody concentration, and antigen-retrieval methods）.
　Several drugs have been developed that target AR signaling.  Bicalutamide is a widely avail-
able, orally active, non-steroidal anti-androgen that competitively inhibits the actions of androgens 
by binding to cytosolic ARs in target tissues.  One published Phase II trial has explored the 
efficacy of bicalutamide in AR-positive, ER-negative, PR-negative metastatic breast cancer 
patients3）.  In that trial, patients were eligible to receive bicalutamide at a dose of 150 mg daily 
if either the primary or a metastatic site was AR positive.  The 6-month clinical benet rate 
was found to be 19% （95% CI 7 %-39%）.  The median progression-free survival was found 
to be 12 weeks （95% CI 11-22 weeks）.  The most common, possibly drug-related, toxicities 
of any grade were fatigue （21%）, hot flashes （21%）, limb edema （21%）, and elevations in 
aspartate aminotransferase （25%） and alkaline aminotransferase （21%）.  Grade 1 toxicities were 
reported by more than 10 % of patients.  There were a few Grade 2 or 3 toxicities, but no 
Grade 4 or 5 toxicities.  Recently, a case report has been published on the complete response 
of metastatic AR-positive breast cancer to bicalutamide after 4 months, which is ongoing 12 
months after treatment started12）.  Bicalutamide caused only Grade 1 fatigue and Grade 1 
hot flashes （CTCAE criteria v4.03 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_
QuickReference_8.5x11.pdf）.
　Enzalutamide, another AR inhibitor, targets multiple steps in the AR signaling pathway in 
tumor cells.  It achieves this through competitive inhibition of androgen binding to ARs, as well 
as blockade of both AR nuclear translocation and AR interaction with DNA.  A Phase II trial 
aiming to validate the clinical activity and safety of enzalutamide is currently enrolling women 
with advanced AR-positive TNBC and will be terminated in 2016 （ClinicalTrials.gov Identier 
NCT01889238）.
　Orteronel is an oral non-steroidal androgen synthesis inhibitor that selectively inhibits 17,20 
lyase.  This enzyme, which is present in both the testes and adrenal glands, is central to the 
production of steroidal androgens.  A Phase II trial testing orteronel as monotherapy in patients 
with metastatic AR-positive breast cancer commenced in January 2014 （ClinicalTrials.gov Identi-
er NCT01990209）.  
　In conclusion, the AR has been demonstrated to play a role in breast cancer.  From a clinical 
perspective, AR expression may be associated with a favorable prognosis.  However, more stud-
ies are needed to clarify the relationships between AR, breast cancer, and the efcacy of anti-
androgen therapy.  The present case report supports the efcacy of anti-androgen therapy for 
AR-positive TNBC.  Further evaluation of AR expression will be important for the development 
of new treatment strategies for AR-positive TNBC.
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